http://www.fpnotebook.com/
MetronidazoleAka: Flagyl
- Indications
- Protozoal Infection
- Anaerobic Bacteria infection
- Pharmacokinetics
- Half-life: 8 hours
- Renal excretion
- Dosing: Children
- Dose
- Load: Metronidazole 15 mg/kg IV
- Maintenance: Metronidazole 7.5 mg/kg/dose
- Interval
- First week of life: q12 hours
- After first week of life: q 8hours
- Dose
- Dosing: Adult
- Intravenous
- Loading dose: 15 mg/kg up to 1000 mg IV
- Maintenance dose: 7.5 mg/kg up to 500 mg IV q6-8 hour
- Oral dose: 250 to 750 mg PO tid
- Intravenous
- Adverse Effects
- Antabuse like effect (Never use with Alcohol)
- Paresthesias with long-term use
- Gastrointestinal intolerance
- Pregnancy
- Class B Medication (Avoid in first trimester pregnancy)
- Directions
- Taking with food decreases gastric irritation
- References
Metronidazole (C0025872) | |
|---|---|
| Definition (MSH) | A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. It has also been proposed as a radiation sensitizer for hypoxic cells. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985, p133), this substance may reasonably be anticipated to be a carcinogen (Merck, 11th ed). |
| Definition (CSP) | antiprotozoal and antibacterial effective against obligate anaerobes. |
| Definition (NCI) | A drug used to treat bacterial, fungal, and parasitic infections. It is also being studied in the treatment of some cancers. |
| Definition (PDQ) | A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39503&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=39503&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C651" NCI Thesaurus) |
| Definition (NCI) | A synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. Although its mechanism of action is not fully elucidated, un-ionized metronidazole is readily taken up by obligate anaerobic organisms and is subsequently reduced by low-redox potential electron-transport proteins to an active, intermediate product. Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D008795 |
| English | 2 Methyl 5 nitroimidazole 1 ethanol, 2-Methyl-5-nitroimidazole-1-ethanol, METRO, Metronidazole, METRONIDAZOLE PREPARATION, Metronidazole product |
| Spanish | metronidazol |
| Parent Concepts | Nitroimidazoles (C0028179), Antiprotozoal Agents (C0003416), Imidazoles (C0020924), Anti-Bacterial Agents (C0279516), Antitrichomonal Agents (C0003447), Protein Synthesis Inhibitors (C0033671), [AM900] ANTI-INFECTIVES, OTHER (C0973485), [DE752] ANTIACNE AGENTS, TOPICAL (C0973530), [GA303] H.PYLORI AGENTS (C0973551), [GU300] ANTI-INFECTIVES, VAGINAL (C0973559), Metronidazole (C0025872), Vaginal metronidazole (C0595096), Drug allergen (C1320237), Dermatological Antibacterials (C1579273), Miscellaneous Antibacterials (C1579351) |
| Sources | AOD, CSP, LCH, LNC, MSH, MTH, MTHFDA, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Flagyl (C0699678) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | D008795 |
| English | Flagyl |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
